Stichting Hemato-oncologie Voor Volwassenen Nederland
Clinical trials sponsored by Stichting Hemato-oncologie Voor Volwassenen Nederland, explained in plain language.
-
New pill targets leukemia's genetic weak spot in phase 3 trial
Disease control Recruiting nowThis study tests whether adding the experimental drug bleximenib to standard chemotherapy improves outcomes for adults with newly diagnosed acute myeloid leukemia (AML) that has a KMT2A rearrangement or NPM1 mutation. Bleximenib blocks a protein interaction that helps leukemia ce…
Phase: PHASE3 • Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland • Aim: Disease control
Last updated May 22, 2026 14:01 UTC
-
New hope for CLL patients: drug combo targets relapsed disease
Disease control Recruiting nowThis study tests a combination of two drugs, venetoclax and acalabrutinib, in people with chronic lymphocytic leukemia (CLL) whose cancer returned after initial treatment with venetoclax and an antibody. The goal is to see if this new combo can make the cancer undetectable in the…
Phase: PHASE2 • Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
Heart shield for lymphoma patients: new trial aims to stop Chemo's hidden danger
Prevention Recruiting nowThis study tests whether the drug dexrazoxane can prevent heart damage caused by chemotherapy in people with diffuse large B-cell lymphoma (DLBCL). About 324 patients will receive either standard chemo plus dexrazoxane or standard chemo alone. The goal is to see if the drug prote…
Phase: PHASE3 • Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland • Aim: Prevention
Last updated May 26, 2026 04:34 UTC